» Articles » PMID: 37759462

The Role and Therapeutic Targeting of CCR5 in Breast Cancer

Overview
Journal Cells
Publisher MDPI
Date 2023 Sep 28
PMID 37759462
Authors
Affiliations
Soon will be listed here.
Abstract

The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, recent studies have shown the induction of CCR5 on the surface of breast cancer epithelial cells. The function of CCR5 on breast cancer epithelial cells includes the induction of aberrant cell survival signaling and tropism towards chemo attractants. As CCR5 is not expressed on normal epithelium, the receptor provides a potential useful target for therapy. Inhibitors of CCR5 (CCR5i), either small molecules (maraviroc, vicriviroc) or humanized monoclonal antibodies (leronlimab) have shown anti-tumor and anti-metastatic properties in preclinical studies. In early clinical studies, reviewed herein, CCR5i have shown promising results and evidence for effects on both the tumor and the anti-tumor immune response. Current clinical studies have therefore included combination therapy approaches with checkpoint inhibitors.

Citing Articles

The Use of Biologics for Targeting GPCRs in Metastatic Cancers.

McBrien C, OConnell D BioTech (Basel). 2025; 14(1).

PMID: 39982274 PMC: 11843943. DOI: 10.3390/biotech14010007.


Association of the SNPs in CCL2 and CXCL12 genes with the susceptibility to breast cancer: a case-control study in China.

Zhao D, Yu X, Huang H, Zou S, Zhu P, Lin Y Front Oncol. 2024; 14:1475979.

PMID: 39703847 PMC: 11655334. DOI: 10.3389/fonc.2024.1475979.

References
1.
Lamouille S, Connolly E, Smyth J, Akhurst R, Derynck R . TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci. 2012; 125(Pt 5):1259-73. PMC: 3324583. DOI: 10.1242/jcs.095299. View

2.
Parkes E, Walker S, Taggart L, McCabe N, Knight L, Wilkinson R . Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. J Natl Cancer Inst. 2016; 109(1). PMC: 5441301. DOI: 10.1093/jnci/djw199. View

3.
DOronzo S, Lovero D, Palmirotta R, Stucci L, Tucci M, Felici C . Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer. Sci Rep. 2019; 9(1):17276. PMC: 6872745. DOI: 10.1038/s41598-019-53660-x. View

4.
Zhao L, Wu X, Li T, Luo J, Dong D . ctcRbase: the gene expression database of circulating tumor cells and microemboli. Database (Oxford). 2020; 2020. PMC: 7158883. DOI: 10.1093/database/baaa020. View

5.
Patel R, Hernandez R, Carlson P, Grudzinski J, Bates A, Jagodinsky J . Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021; 13(602). PMC: 8449934. DOI: 10.1126/scitranslmed.abb3631. View